JP2024524933A - Ｉｄｈ変異体阻害剤およびその使用 - Google Patents

Ｉｄｈ変異体阻害剤およびその使用 Download PDF

Info

Publication number
JP2024524933A
JP2024524933A JP2023577688A JP2023577688A JP2024524933A JP 2024524933 A JP2024524933 A JP 2024524933A JP 2023577688 A JP2023577688 A JP 2023577688A JP 2023577688 A JP2023577688 A JP 2023577688A JP 2024524933 A JP2024524933 A JP 2024524933A
Authority
JP
Japan
Prior art keywords
compound
compounds
pharma
general formula
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577688A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524933A5 (OSRAM
Inventor
シエ，ユリ
ファン，ホウシン
チエン，リフゥイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wigen Biomedicine Technology Shanghai Co Ltd
Original Assignee
Wigen Biomedicine Technology Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wigen Biomedicine Technology Shanghai Co Ltd filed Critical Wigen Biomedicine Technology Shanghai Co Ltd
Publication of JP2024524933A publication Critical patent/JP2024524933A/ja
Publication of JP2024524933A5 publication Critical patent/JP2024524933A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023577688A 2021-06-15 2022-06-15 Ｉｄｈ変異体阻害剤およびその使用 Pending JP2024524933A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110661394.5 2021-06-15
CN202110661394 2021-06-15
PCT/CN2022/099018 WO2022262784A1 (zh) 2021-06-15 2022-06-15 Idh突变体抑制剂及其用途

Publications (2)

Publication Number Publication Date
JP2024524933A true JP2024524933A (ja) 2024-07-09
JP2024524933A5 JP2024524933A5 (OSRAM) 2025-06-23

Family

ID=84526875

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577688A Pending JP2024524933A (ja) 2021-06-15 2022-06-15 Ｉｄｈ変異体阻害剤およびその使用

Country Status (10)

Country Link
US (1) US20240208978A1 (OSRAM)
EP (1) EP4356914A4 (OSRAM)
JP (1) JP2024524933A (OSRAM)
KR (1) KR20240021774A (OSRAM)
CN (1) CN117460512A (OSRAM)
AU (1) AU2022294860A1 (OSRAM)
BR (1) BR112023024454A2 (OSRAM)
CA (1) CA3217608A1 (OSRAM)
MX (1) MX2023013664A (OSRAM)
WO (1) WO2022262784A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026035776A1 (en) * 2024-08-05 2026-02-12 Frontier Medicines Corporation Pi3k-alpha binding compounds and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016171755A1 (en) * 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
JP2018525369A (ja) * 2015-07-27 2018-09-06 イーライ リリー アンド カンパニー ７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物及び変異体ｉｄｈ１阻害剤としてのそれらの使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012184205A (ja) * 2011-03-08 2012-09-27 Dainippon Sumitomo Pharma Co Ltd ２−アミノ置換８−オキソジヒドロプリン誘導体
PT3415517T (pt) * 2012-09-28 2022-05-13 Takeda Pharmaceuticals Co Forma cristalina de 1-(4-1-(2,6-difluorobenzil)-5- dimetilaminometil-3-(6-metoxipiridazin-3-il)-2,4-dioxo- 1,2,3,4-tetrahidrotieno(2,3-d)-pirimidin-6-il)fenil)-3- metoxiureia
KR20150131224A (ko) * 2013-03-14 2015-11-24 노파르티스 아게 돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
MA46064B1 (fr) * 2014-09-19 2020-04-30 Forma Therapeutics Inc Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase
ES2814290T3 (es) 2016-06-06 2021-03-26 Lilly Co Eli Inhibidores de IDH1 mutante
CN107556366B (zh) * 2016-06-30 2025-02-07 上海海和药物研究开发股份有限公司 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途
EP3489230B1 (en) * 2016-07-21 2021-12-08 Nanjing Sanhome Pharmaceutical Co., Ltd. Chemical compound of isocitrate dehydrogenase inhibitor, and application thereof
PH12019501328B1 (en) 2016-12-16 2023-05-12 Lilly Co Eli 7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors
WO2020048347A1 (zh) * 2018-09-04 2020-03-12 上海再极医药科技有限公司 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用
US20200206233A1 (en) * 2018-12-31 2020-07-02 Integral Biosciences Private Limited Heterocyclic compounds as mutant idh inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016171755A1 (en) * 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
JP2018525369A (ja) * 2015-07-27 2018-09-06 イーライ リリー アンド カンパニー ７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物及び変異体ｉｄｈ１阻害剤としてのそれらの使用

Also Published As

Publication number Publication date
MX2023013664A (es) 2024-01-08
AU2022294860A1 (en) 2024-01-25
BR112023024454A2 (pt) 2024-02-06
WO2022262784A1 (zh) 2022-12-22
EP4356914A4 (en) 2025-01-08
EP4356914A1 (en) 2024-04-24
US20240208978A1 (en) 2024-06-27
CA3217608A1 (en) 2022-12-22
CN117460512A (zh) 2024-01-26
KR20240021774A (ko) 2024-02-19

Similar Documents

Publication Publication Date Title
JP2024514703A (ja) ピペラジン構造を有するｐａｒｐ阻害剤、その調製方法およびその医薬的使用
JP7773987B2 (ja) スピロ環含有キナゾリン化合物
JP2024529070A (ja) Ａｔｒ阻害剤としてのナフチリジン誘導体およびその調製方法
AU2011208139B2 (en) Piperazine compound having a PGDS inhibitory effect
US20150218127A1 (en) Carbamate/urea derivatives
EP4365170A1 (en) Amide compound and use thereof
EP3354647B1 (en) Egfr kinase inhibitor and preparation method and use thereof
JP7796674B2 (ja) Ｗｅｅ－１阻害剤としてのピラゾロ［３，４－ｄ］ピリミジン－３－オン誘導体
CN111606890A (zh) 含丙烯酰基的核转运调节剂及其用途
KR20240021774A (ko) Idh 돌연변이 억제제 및 이의 용도
WO2025153047A1 (zh) 喜树碱衍生物及其制备方法和应用
RU2860311C2 (ru) Ингибитор мутанта idh и его применение
CN113880804A (zh) 新型苯并咪唑化合物
JP7777544B2 (ja) 新規ピラジン化合物
CN115768775B (zh) Idh突变体抑制剂及其用途
RU2857202C2 (ru) Ингибитор parp, содержащий пиперазиновую структуру, способ его получения и фармацевтическое применение
WO2022063299A1 (zh) 用作dhodh抑制剂的1,2,4-三唑酮衍生物
JP2025540298A (ja) Ｈｄａｃ阻害剤およびその使用
JP2024515318A (ja) Ｗｅｅ－１阻害剤としての縮合環状化合物、その調製方法およびその使用
JP2024105489A (ja) Μｇａτ２阻害活性を有する縮合環誘導体の製造方法
WO2022171135A1 (zh) 含螺环的喹唑啉衍生物
CN121517424A (zh) PI3Kα抑制剂及其制备方法和医药用途
JP3000301B2 (ja) ３−（ビス−置換フェニルメチレン）オキシインド−ル誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260508